This article is more than 5 years old. Information may no longer be current.
Recent updates in atopic dermatitis on tape strips, abrocitinib, Dupixent and more
Click Here to Manage Email Alerts
Researchers have identified a minimally invasive technique using tape strips to study the phenotype and specific biomarkers in children with atopic dermatitis, in a popular story at Healio Dermatology, just in time for National Eczema Awareness Month.
Emma Guttman-Yassky, MD, PhD, of Icahn School of Medicine at Mount Sinai Medical Center, explains more about this innovative approach in the link below.
In other news, at the University of Michigan, Johann E. Gudjonsson, MD, PhD, and colleagues provide a collaborative experience for research on inflammatory skin diseases with a grant from the NIH.
Read up on six recent updates in atopic dermatitis.
Tape strip approach identifies atopic dermatitis biomarkers in children
“We are constantly seeking a minimally invasive means to get to the [atopic dermatitis] phenotype in children,” study author Emma Guttman-Yassky, MD, PhD, said. “It’s even more important because many clinical trials which have been successful in adults are now moving into children. We have therapeutic development moving into children, and we also need biomarkers to understand treatment responses in children.” Read more.
Oral JAK1 abrocitinib shows short-term efficacy in atopic dermatitis
Findings from a 12-week phase 2b study show significant improvement in the signs and symptoms of atopic dermatitis with once-daily treatment of an oral Janus kinase 1 selective inhibitor, abrocitinib 100 mg or 200 mg. Read more.
University of Michigan offers unique resources for inflammatory skin disease research
“The goal of this center is to provide to the skin research community unique resources and services that are not available anywhere else,” Johann E. Gudjonsson, MD, PhD, said. Read more.
Dupixent does not hamper patch testing in atopic dermatitis
Among 35 patients with atopic dermatitis, 32 patients (91.4%) had comorbid atopic contact dermatitis, determined by positive patch testing and subsequent improvement with allergen avoidance. Read more.
Dermira begins phase 3 study of lebrikizumab in atopic dermatitis
Lebrikizumab is an investigational, monoclonal antibody designed to bind to interleukin-13 (IL-13) to prevent the formation of the IL-13 receptor alpha/IL-4 receptor alpha heterodimer complex and signaling. Read more.
Patient-reported outcome measures with Skindex may yield more comprehensive data
Relying primarily on patient global assessments falls short in determining comprehensive disease severity, but by adding the Skindex instrument or other measures, clinicians may obtain a better evaluation of patient quality of life. Read more.